Abstract
Although the anticonvulsant hypersensitivity syndrome was first described in 1950, confusion still abounds regarding the syndrome. The triad of fever, rash and internal organ involvement occurring 1 to 8 weeks after exposure to an anticonvulsant heralds this rare (1 in 1000 to 10 000 exposures) but serious reaction. Aromatic anticonvulsants [phenytoin, phenobarbital (phenobarbitone) and carba-mazepine] are the most frequently involved drugs; however, there have also been several cases of anticonvulsant hypersensitivity syndrome associated with lamotrigine.
Fever, in conjunction with malaise and pharyngitis, is often the first sign. This is followed by a rash which can range from a simple exanthem to toxic epidermal necrolysis. Internal organ involvement usually involves the liver, although other organs such as the kidney, CNS or lungs may be involved. Hypothyroidism may be a complication in these patients approximately 2 months after occurrence of symptoms.
The aromatic anticonvulsants are metabolised to hydroxylated aromatic compounds, such as arene oxides. If detoxification of this toxic metabolite is insufficient, the toxic metabolite may bind to cellular macromolecules causing cell necrosis or a secondary immunological response. Cross-reactivity among the aromatic anticonvulsants may be as high as 75%. In addition, there is a familial tendency to hypersensitivity to anticonvulsants.
Discontinuation of the anticonvulsant is essential in patients who develop symptoms compatible with anticonvulsant hypersensitivity syndrome. A minimum battery of laboratory tests, such as liver transaminases, complete blood count and urinalysis and serum creatinine, should be performed. Corticosteroids are usually administered if symptoms are severe. Patients with anticonvulsant hypersensitivity syndrome should avoid all aromatic anticonvulsants; benzo-diazepines, valproic acid (sodium valproate) or one of the newer anticonvulsants can be used for seizure control. However, valproic acid should be used very cautiously in the presence of hepatitis. There is no evidence that lamotrigine cross-reacts with aromatic anticonvulsants. In addition, family counselling is a vital component of patient management.
Similar content being viewed by others
References
Vittorio C, Muglia J. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285–90
Anonymous. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises. Case 26-1996: a seven-year-old boy with fever, lymphadenopathy, hepatosplenomegaly, and prominent eosinophilia. N Engl J Med 1996; 335: 577-84
Konishi G, Naganuma Y, Hongo K, et al. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993; 152: 605–8
Shear N, Spielberg S. Anticonvulsant hypersensitivity syndrome, in vitro assessment of risk. J Clin Invest 1988; 82: 1826–32
Haruda F. Phenytoin hypersensitivity: 38 cases. Neurology 1979; 29: 1480–5
Handfield-Jones S, Jenkins R, Whittaker S, et al. The anticon-vulsant hypersensitivity syndrome. Br JDermatol 1993; 129: 175–7
Tomsick R. The phenytoin syndrome. Cutis 1983; 32: 535–41
Prosser T, Lander R. Phenytoin-induced hypersensitivity reactions. Clin Pharm 1987; 6: 728–34
Rivey M, Stone J. Carbamazepine hypersensitivity reaction. Brain Inj 1991; 5: 57–62
Parker W, Shearer C. Phenytoin hepatotoxicity: a case report and review. Neurology 1979; 29: 175–8
Lane T, Peterson E. Hepatitis as a manifestation of phenobarbital hypersensitivity. South Med J 1984; 77: 94
Ting S, Dunsky E. Diphenylhydantoin-induced hepatitis. Ann Allergy 1982; 48: 331–2
Olsson R, Zettergren L. Anticonvulsant-induced liver damage. Am J Gastroenterol 1988; 83: 576–7
Smythe M, Unstead G. Phenytoin hepatotoxicity: a review of the literature. Drug Intell Clin Pharm 1989; 23: 13–8
Schlienger R, Shear N. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998; 39 Suppl.: S3–S7
Merritt H, Putnam T. Sodium diphenylhydantoinate in treatment of convulsive disorders: toxic symptoms and their prevention. Arch Neurol Psychiatry 1939; 42: 1053–8
Chaiken R, Goldberg B, Segal J. Dilantin sensitivity: report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950; 242: 897–8
Tennis P, Stern R. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: arecord linkage study. Neurology 1997; 49: 542–6
Schlienger R, Oh P, Knowles S, et al. Quantifying the costs of serious adverse drug reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl.: S27–S32
Roujeau JC, Stern R. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272–85
Spielberg S, Shear N, Hutson N, et al. In-vitro assessment of hypersensitivity syndrome associated with sorbinil. Ann Intern Med 1991; 114: 720–4
Knowles S, Shapiro L, Shear N. Serious adverse reactions induced by minocycline: a report of 13 patients and review of the literature. Arch Dermatol 1996; 132(8): 934–9
Schlienger R, Knowles S, Shear N. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998; 51: 1172–5
Dhar G, Pierach CA, Ahamed PN, et al. Diphenylhydantoin-induced hepatic necrosis. Postgrad Med 1974; 56: 128–34
Mullick F, Ishak K. Hepatic injury associated with diphenylhydantoin therapy. Am J Clin Pathol 1980; 74: 442–52
Cowan L, Bodensteiner JB, Leviton A, et al. Prevalence of the epilepsies in children and adolescents. Epilepsia 1989; 30: 94–106
Shapiro L, Neumann M, Malkiewicz I, et al. Black race may predict increased severe cutaneous adverse reactions in patients with phenytoin hypersensitivity reactions. Clin Invest Med 1998; 21: 515
Hyson C, Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997; 24: 245–9
Rapp R, Norton J, Young B, et al. Cutaneous reactions in head-injured patients receiving phenytoin for seizure prophylaxis. Neurosurgery 1983; 13: 272–5
Wilson T, Hojer B, Tomson G, et al. High incidence of a concentration-dependent skin reaction in children treated with phenytoin. BMJ 1978; 1: 1583–6
Chadwick D, Shaw M, Foy P, et al. Serum anticonvulsant concentrations and the risk of drug-induced skin eruptions. J Neurol Neurosurg Psychiatry 1984; 47: 642–4
Shapiro L, Shear N. Mechanisms of drug reactions: the metabolic track. Sem Cutan Med Surg 1996; 15: 217–27
Taliercio C, Olney B, Lie J. Myocarditis related to drug hypersensitivity. Mayo Clin Proc 1985; 60: 463–8
Stephan W, Parks R, Tempest B. Acute hypersensitivity pneumonitis associated with carbamazepine therapy. Chest 1978; 74: 463–4
Murphy D, Kronick J, Rieder M. Acute respiratory failure mediated by reactive drug metabolites. Biol Neonat 1995; 67: 223–9
Kleier R, Breneman D, Boiko S. Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol 1991; 127: 1361–4
Morkunas A, Miller M. Anticonvulsant hypersensitivity syndrome. Med Toxicol 1997; 13: 727–39
Robbie M, Scurry J, Stevenson P. Carbamazepine-induced severe systemic hypersensitivity reaction with eosinophilia. Drug Intell Clin Pharm 1988; 22: 783–4
Gupta A, Eggo M, Uetrecht J, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992; 51: 56–67
Callot V, Roujeau J, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome: two different clinical entities. Arch Dermatol 1996; 123: 1315–21
Schreiber M, McGregor J. Pseudolymphoma syndrome. Arch Demi 1968; 97: 297–300
Sinnige H, Boender C, Kuypers E, et al. Carbamazepine-induced pseudolymphoma and immune dysregulation. J Intern Med 1990; 227: 355–8
Saltzstein S, Ackerman L. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer 1959; 12: 164–82
Souteyrand P, d’Incan M. Drug-induced mycosis-fungoides-like lesions. Curr Probl Dermatol 1990; 19: 176–82
Wilden J, Scott C. A pseudolymphomatous reaction in soft tissue associated with phenytoin sodium. J Clin Pathol 1978; 31: 76–1764
Rijlaarsdam J, Scheffer E, Meijer CJ, et al. Cutaneous pseudo-T-cell lymphomas: a clinicopathologic study of 20 patients. Cancer 1992; 69: 717–24
d’Incan M, Souteyrand P, Bignon Y, et al. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sezary syndrome. Arch Dermatol 1992; 128: 1371–4
Yates P, Stockdill G, McIntyre M. Hypersensitivity to carbamazepine presenting as pseudolymphoma. J Clin Pathol 1986; 39: 1224–8
Shuttleworth D, Graham-Brown R, Williams A, et al. Pseudolymphoma associated with carbmazepine. Clin Exp Dermatol 1984; 9: 421–3
Sigal-Nahum M, Petit A, Gaulier A, et al. A nodular cutaneous lymphoproliferative disorder during carbamazepine administration. Br J Dermatol 1992; 127: 545–7
Rijlaarsdam U, Scheffer E, Meijer C, et al. Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991; 24: 216–20
Wolf R, Kahane E, Sandbank M. Mycosis fungoides-like lesions associated with phenytoin therapy. Arch Dermatol 1985;121: 1181–2
Rosenthal C, Noguera C, Coppola A, et al. Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer 1982; 49: 2305–14
Welykyj S, Gradini R, Nakao J, et al. Carbamazepine-induced eruption histologically mimicking mycosis fungoides. J CutanPathol 1990; 17: 111–6
De Vriese A, Philippe J, Van Renterghem D, et al. Carbamazepine hypersensitivity syndrome: report of four cases and review of the literature. Medicine 1995; 74: 144–51
Savich R, Traisman H. Phenobarbital hypersensitivity reaction. Ill Med J 1986; 169: 232–4
Plantin P, Cartier H, Le Bihan G, et al. Syndrome d’hypersensibilite medicamenteuse au cours d’un traitement par acide valproique. Presse Med 1995; 24: 1624
Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359–67
Besag F, Wallace S, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995; 127: 991–7
Jones D, Chiap V, Resor S, et al. Phenytoin-like hypersensitivity associated with lamotrigine. J Am Acad Dermatol 1997; 36: 1016–8
Chaffin J, Davis S. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacotherapy 1997; 31: 720–3
Makin A, Fitt S, Williams R, et al. Fulminant hepatic failure induced by lamotrigine. BMJ 1995; 311: 292
Nicholson R, Kelly K, Grant I. Leucopenia associated with lamotrigine. BMJ 1995; 310: 504
Sullivan J, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Aust J Dermatol 1996; 37: 208–12
Schaub J, Williamson P, Barnes E, et al. Multisystem adverse reaction to lamotrigine [letter]. Lancet 1994; 344: 481
Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995; 33: 595–7
Wadelius M, Karlsson T, Wadelius C, et al. Lamotrigine and toxic epidermal necrolysis [letter]. Lancet 1996; 348: 1041
Page R, O’Neil M, Yarbrough D, et al. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998; 18: 392–8
Chattergoon D, McGuigan M, Koren G, et al. Multiorgan dysfunction and disseminated intravascular coagulopathy in children receiving lamotrigine and valproic acid. Neurology 1997; 49: 1442–4
Mitchell P. Paediatric lamotrigine use hit by rash reports. Lancet 1997; 349: 1080
Richens A. Safety of lamotrigine. Epilepsia 1994; 35 Suppl.: S37–40
Yuen A, Land G, Weatherley B, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511–3
Spielberg S. In vitro analysis of idiosyncratic drug reactions. Clin Biochem 1986; 19: 142–4
Houwerzijl J, DeGast G, Nater J. Patch tests in drug eruptions. Contact Dermatitis 1975; 1: 180–92
Jones M, Fernandez-Herrera J, Dorado J, et al. Epicutaneous test in carbamazepine cutaneous reactions. Dermatology 1994; 188: 18–20
Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993; 29: 254–7
Romaguera C, Grimalt F, Vilaplana J, et al. Erythroderma from carbamazepine. Contact Dermatitis 1989; 20: 304–5
Scerri L, Shall L, Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome — pathogenic and diagnostic considerations. Clin Exp Dermatol 1993; 18: 540–2
Puig L, Nadal C, Fernandex-Figueras M, et al. Carbamazepine-induced drug rashes: diagnostic value of patch tests depends on clinico-pathologic presentation. Contact Dermatitis 1996; 34: 435–7
Houwerzijl J, De Gast G, Nater J, et al. Lymphocyte-stimulation tests and patch tests in carbamazepine hypersensitivity. Clin Exp Immunol 1977; 29: 272–7
Silva R, Machado A, Brandao M, et al. Patch test diagnosis in carbamazepine erythroderma. Contact Dermatitis 1986; 15: 254–5
Spielberg S, Gordon G, Blake D, et al. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 1981; 217: 386–9
Riley F, Leeder S. In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol 1995; 99: 1–6
Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions. Arch Dermatol 1995; 131: 544–51
Spielberg S, Gordon G, Blake D, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl JMed 1981; 305: 722–7
Zanni M, von Greyerz S, Schnyder B, et al. T cell reactions in patients showing adverse immune reactions to drugs. Inflamm Res 1996; 45 Suppl.: S79–84
Merk H, Baron J, Hertl M, et al. Lymphocyte activation in allergic reactions elicited by small molecular-weight compounds. Int Arch Allergy Immunol 1997; 113: 173–6
Pirmohamed M, Graham A, Roberts P, et al. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991; 32: 741–9
Gleichmann H. Studies on the mechanism of drug sensitization: T-cell dependent popliteal lymph node reaction to diphenylhydantoin. Clin Immunol Immunopathol 1981; 18: 203–11
Murphy J, Mashman J, Miller J, et al. Suppression of carbamazepine-induced rash with prednisone. Neurology 1991; 41: 144–5
Vick N. Suppression of carbamazepine-induced skin rash with prednisone. New Engl J Med 1983; 309: 1193–4
Smith M, Bleck T. Convulsive disorders: toxicity of anticonvul-sants. Clin Neuropharmacol 1991; 14: 97–115
Gaedigk A, Spielberg S, Grant D. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4: 142–53
Friedman P, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130: 598–604
Pirmohamed M, Kitteringham N, Breckenridge A, et al. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol 1992; 33: 183–6
Leeder J, Riley R, Cook V, et al. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther 1992; 263: 360–7
Alldredge B, Knutsen A, Ferriero D. Antiepileptic drug hypersensitivity syndrome: in vitro and clinical observations. Pediatr Neurol 1994; 10: 169–71
Gennis M, Vemuri R, Burns E, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91: 631–4
Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433–43
Knowles S, Shapiro L, Shear N. Serious dermatologic reactions in children. Curr Opin Pediatr 1997; 9: 388–95
Chopra S, Levell NJ, Cowley G, et al. Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Br J Dermatol 1996; 134: 1109–12
Sheretz E, Jegasothy B, Lazarus G. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. J Am Acad Dermatol 1985; 12: 178–81
Chaidemenos G, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997; 36: 218–21
Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–3
Eames P. Adverse reactions to carbamazepine managed by desensitization. Lancet 1989; I: 509–10
Purves S, Hashimoto S, Tse K. Successful desensitization of patients with carbamazepine allergy [abstract]. Can J Neurol Sci 1988; 15: 237
Smith H, Newton R. Adverse reactions to carbamazepine managed by desensitisation [letter]. Lancet 1985; I: 753
Watts D, Bird J. Oxcarbazepine sensitivity treated by desensitisation [letter]. BMJ 1991; 541: 376
Zakrzewska J, Ivanyi L. In vitro lymphocyte proliferation by carbmazepine, carbamazepine-10,11 epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988; 82: 110–5
Reents S, Luginbuhl W, Davis S. Phenytoin-carbamazepine cross-sensitivity. Ann Pharmacother 1989; 23: 235–6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Knowles, S.R., Shapiro, L.E. & Shear, N.H. Anticonvulsant Hypersensitivity Syndrome. Drug-Safety 21, 489–501 (1999). https://doi.org/10.2165/00002018-199921060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199921060-00005